New understanding and treatments for osteoporosis (Q37969683)

26 August 2017

New understanding and treatments for osteoporosis (English)

1 reference

26 August 2017

0 references

G Mazziotti

1

1 reference

26 August 2017

J Bilezikian

2

1 reference

26 August 2017

E Canalis

3

1 reference

26 August 2017

D Cocchi

4

1 reference

26 August 2017

A Giustina

5

1 reference

26 August 2017

1 February 2012

1 reference

26 August 2017

1 reference

26 August 2017

41

1 reference

26 August 2017

1

1 reference

26 August 2017

58-69

1 reference

https://scigraph.springernature.com/pub.10.1007/s12020-011-9570-2

26 August 2017

0 references

cites work

A model of lifetime osteoporosis impact.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Oxidative stress stimulates apoptosis and activates NF-kappaB in osteoblastic cells via a PKCbeta/p66shc signaling cascade: counter regulation by estrogens or androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

De-fense! De-fense! De-fense: scavenging H2O2 while making cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

21 January 2018

Notch and the skeleton

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/beta-catenin but not bone morphogenetic protein signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Notch inhibits osteoblast differentiation and causes osteopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Reciprocal regulation of Notch and nuclear factor of activated T-cells (NFAT) c1 transactivation in osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Truncating mutations in the last exon of NOTCH2 cause a rare skeletal disorder with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and progressive bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Physiological changes in extracellular calcium concentration directly control osteoblast function in the absence of calciotropic hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Mitogenic action of calcium-sensing receptor on rat calvarial osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Targeting the stem cell niche: squeezing blood from bones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Novel treatments for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Mechanisms of anabolic therapies for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

T cells: critical bone regulators in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

T cells potentiate PTH-induced cortical bone loss through CD40L signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Effects of teriparatide retreatment in osteoporotic men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Sequential therapy in the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

The effect of a single dose of osteoprotegerin in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Osteoporosis: now and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Drug-induced osteoporosis: mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

RANK ligand and osteoprotegerin in myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Mechanisms of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

The role of osteoclast-associated receptor in osteoimmunology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

The long and the short of bone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Regulation of cancer cell migration and bone metastasis by RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Targeting sclerostin as potential treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Bisphosphonates and atypical femoral fractures: a time for reflection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Safety of long-term bisphosphonate therapy for the management of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Atrial fibrillation and bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

High glucose stimulates adipogenic and inhibits osteogenic differentiation in MG-63 cells through cAMP/protein kinase A/extracellular signal-regulated kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Diminished bone formation during diabetic fracture healing is related to the premature resorption of cartilage associated with increased osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

The effects of the receptor for advanced glycation end products (RAGE) on bone metabolism under physiological and diabetic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Growth hormone, insulin-like growth factors, and the skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Osteoporosis among patients with type 1 and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Glucocorticoid-induced osteoporosis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Prevalence of vertebral fractures in men with acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Vertebral fractures in males with prolactinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3-kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Effects of glucose and its modulation by insulin and estradiol on BMSC differentiation into osteoblastic lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Skeletal consequences of thiazolidinedione therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

The risk of fractures associated with thiazolidinediones: a self-controlled case-series study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Thiazolidinediones and fractures in men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9570-2

Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.

21 January 2018

1 reference

12 December 2020

Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research

1 reference

12 December 2020

Caught up in a Wnt storm: Wnt signaling in cancer

1 reference

12 December 2020

OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats

1 reference

12 December 2020

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update

1 reference

12 December 2020

Generalised bone loss in patients with early rheumatoid arthritis

1 reference

12 December 2020

Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate

1 reference

12 December 2020

RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma

1 reference

12 December 2020

Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women

1 reference

12 December 2020

Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials

1 reference

12 December 2020

Calcium-sensing receptor in mature osteoclasts, which are bone resorbing cells

1 reference

12 December 2020

Bisphosphonate associated osteonecrosis of the jaw.

1 reference

12 December 2020

The use of combination therapy in the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Influence of diabetes mellitus on vertebral fractures in men with acromegaly

1 reference

12 December 2020

Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERalpha

1 reference

12 December 2020

Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease

1 reference

12 December 2020

One NOTCH Further: Jagged 1 in Bone Metastasis

1 reference

12 December 2020

Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy

1 reference

12 December 2020

The OPG/RANKL/RANK system in metabolic bone diseases.

1 reference

12 December 2020

Extracellular calcium sensing and extracellular calcium signaling

1 reference

12 December 2020

Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study

1 reference

12 December 2020

Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial

1 reference

12 December 2020

Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density

1 reference

12 December 2020

Combination antiresorptive and osteoanabolic therapy for osteoporosis: we are not there yet

1 reference

12 December 2020

The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study

1 reference

12 December 2020

10.1007/S12020-011-9570-2

Identifiers

DOI

1 reference

26 August 2017

1 reference